stock-detail (MYGN)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

Scientists Work To Protect The Kidneys From Powerful Cancer Drug

6/15/2016 11:05 am

(Jagwire/Augusta University) June 13, 2016 - Researchers want to turn the tide by protecting the kidneys while improving cisplatin’s efficacy against cancer.

Improved Survival For Adult Acute Lymphoblastic Leukaemia (All) Patients

6/13/2016 12:00 pm

(EHA 2016) June 11, 2016 - Historical survival for patients 18-45 years with ALL is approximately 40%. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Sunday at ASCO: Plenary Shows Progress in Myeloma

6/5/2016 06:00 pm

(Medscape Medical News) June 5, 2016 - Among the best clinical data selected for the plenary session is the CASTOR study, showing impressive progression-free survival in multiple myeloma.

FDA OKs First Liquid Biopsy for Lung Cancer Mutation

6/2/2016 11:03 am

(Medscape Medical News) June 1, 2016 - The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients.

FDA Expands Label for Palbociclib (Ibrance) in Metastatic Breast Cancer

2/22/2016 01:00 pm

(Managed Care magazine) Feb 22, 2016 - The FDA has approved a new indication expanding the use of palbociclib (Ibrance, Pfizer) 125-mg capsules, a therapy for metastatic breast cancer.

Durvalumab Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients With PD-L1 Positive Urothelial Bladder Cancer

2/17/2016 07:01 am

(AstraZeneca) Feb 17, 2016 - AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1), for the treatment of patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer whose tumour has progressed during or after one standard platinum-based regimen.

Gene Previously Observed Only in Brain is Important Driver of Metastatic Breast Cancer

2/12/2016 11:04 am

(The Wistar Institute) Feb 12, 2016 - Scientists from The Wistar Institute have shown that one gene that was once thought only to be found in the brain is also expressed in breast cancer and helps promote the growth and spread of the disease.

MabVax Therapeutics Receives FDA Authorization for Phase I Clinical Trial with 89Zr-HuMab-5B1 as PET Imaging Agent for Pancreatic Cancer

2/2/2016 12:01 pm

(TheStreet) Feb 2, 2016 - MabVax Therapeutics Holdings, Inc. announces receipt of notice from the U.S. Food and Drug Administration (FDA) authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer.

Insurer’s Approval Of Genetic Testing For Some Cancers Raises Questions

2/2/2016 12:00 pm

(Kaiser Health News) Feb 2, 2016 - Pennsylvania-based Independence Blue Cross’ announcement that it will cover a complex type of genetic testing for some cancer patients thrusts the insurer into an ongoing debate about how to handle an increasing array of these expensive tests.

NantWorks Enters into Exclusive License Agreement with Amgen to Target Cancer c-Met Receptor

9/14/2015 11:01 am

(Yahoo! Finance) Sept 14, 2015 - Acquires exclusive rights to a novel small molecule drug in phase 2 development for gastric and esophageal cancers.

AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment-Naive Chronic Lymphocytic Leukemia

9/14/2015 10:04 am

(StreetInsider) Sept 14, 2015 - AbbVie, a global biopharmaceutical company, announced today that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based on the randomized, multi-center, open-label Phase III RESONATE(TM)-2 (PCYC-1115) trial assessing the use of IMBRUVICA® (ibrutinib) versus chlorambucil in treatment-naive chronic lymphocytic leukemia (CLL) patients aged 65 years or older.

ASCO Signs Joint Letter to Congress Urging Funding Relief for Discretionary Programs

9/11/2015 12:01 pm

(ASCO in Action) Sept 11, 2015 - On Sept. 10, NDD United sent a joint letter to every Member of Congress calling for halts to cuts in discretionary spending programs, including those that are nondefense discretionary (NDD).

First Defendant in Fake Cancer-Drug Case to Be Arraigned

8/19/2015 11:05 am

(Wall Street Journal) Aug 18, 2015 - The first defendant will be arraigned in U.S. federal court next week in connection with an indictment involving Canada Drugs, the Winnipeg-based company accused of selling counterfeit drugs in the U.S.

Web App Helps Researchers Explore Cancer Genetics

7/24/2015 11:02 am

(Brown University) July 23, 2015 - Brown University computer scientists have developed a new interactive tool to help researchers and clinicians explore the genetic underpinnings of cancer.

Merck & Co's Keytruda Approved In EU for Melanoma

7/22/2015 12:05 pm

(PharmaTimes [UK]) July 22, 2015 - Merck & Co’s anti-PD-1 therapy Keytruda has been approved in Europe for the treatment of advanced skin cancer.

Patient Navigators Improve Cancer Screening

5/7/2015 12:00 pm

(Medscape Medical News) May 6, 2015 - For patients who do not complete screening tests for breast, cervical, and colorectal cancer, rates can be significantly increased when information technology is used to identify and target interventions, according to results from a new study.

ImmuneXcite Presents New Preclinical Data at AACR Demonstrating Ability of Its Novel Cancer Immunotherapy Approach to Activate a Potent and Precise T-Cell Attack on Tumors

4/22/2015 11:03 am

(DigitalJournal.com) Apr 21, 2015 - Company’s mAbXcite platform showed significant anti-tumor activity in treatment-resistant models of colorectal and breast cancers.

Oral Milk Thistle Extract Stops Colorectal Cancer Stem Cells from Growing Tumors

4/21/2015 12:01 pm

(UCCC/In the Lab blog) Apr 20, 2015 - Results presented at AACR 2015 show that orally administering the chemical silibinin, purified from milk thistle, slows the ability of colorectal cancer stem cells to grow the disease.

ABRAXANE® Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer

3/2/2015 12:00 pm

(MarketWatch) Mar 2, 2015 - Celgene International Sàrl today announced that the European Commission (EC) has approved ABRAXANE® (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

First Bladder Cancer Guideline to Reduce Variations in Care

2/26/2015 12:01 pm

(NICE) Feb 25, 2015 - NICE’s first guideline on bladder cancer aims to improve the diagnosis and management of the seventh most common cancer in the UK.

FDA Says It Knew Scopes That Allegedly Spread 'Superbug' Could Transmit Bacterial Infections

2/23/2015 12:02 pm

(ABC News) Feb 23, 2015 - The revelation that contaminated endoscopes were cleaned according to manufacturer instructions but still allegedly caused seven people to become infected with a deadly drug-resistant bacteria has raised questions about whether the scopes are too difficult to clean.

'Last Hope' Drug For Prostate Cancer Patients Is Axed From the NHS, in a Move Doctors Call a 'Travesty'

1/9/2015 11:03 am

(The Daily Mail [UK]) Jan 9, 2015 - A ‘last ditch’ drug for prostate cancer sufferers is to be axed from NHS use.

Specialists Split Over HPV Test's Role in Cancer Screening

1/8/2015 10:01 am

(NPR/Shots blog) Jan 8, 2015 - Two medical groups say doctors could replace the Pap smear with a different test to screen many women for cervical cancer.

Boehringer’s Vargatef Approved in the EU for Lung Cancer

12/1/2014 06:04 am

(PMLiVE [UK]) Nov 28, 2014 - The European Commission granted marketing authorisation for Vargatef (nintedanib) in combination with docetaxal for use in adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) after first-line chemotherapy.

Diagnostic Criteria Developed for Cancer-Linked Weight Loss

11/26/2014 10:01 am

(Doctors Lounge/HealthDay News) Nov 25, 2014 - A grading system has been developed for clinically important weight loss (WL) in patients with cancer, which includes the independent prognostic significance of body mass index (BMI) and percent WL, according to research published online Nov. 24 in the Journal of Clinical Oncology.